JB
RLMD icon

Julian Baker’s Relmada Therapeutics RLMD Stock Holding History

Julian Baker’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-495,113
Closed -$18.3M – 119
2022
Q3 		$18.3M Hold
495,113
– – 0.12% 50
2022
Q2 		$9.4M Hold
495,113
– – 0.05% 61
2022
Q1 		$13.4M Hold
495,113
– – 0.08% 58
2021
Q4 		$11.2M Buy
495,113
+294,117
+146% +$6.54M 0.05% 73
2021
Q3 		$5.27M Buy
200,996
+124,396
+162% +$3.33M 0.02% 93
2021
Q2 		$2.45M Buy
+76,600
New +$2.66M 0.01% 109

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Julian Baker's RLMD Position: Q4 2022 in Review

Julian Baker sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 495,113 shares — an estimated $18.3M sold.

Julian Baker first reported a position in RLMD in Q2 2021 and held it in 6 quarters. The position peaked at $18.3M in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • Julian Baker reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Julian Baker sold 495,113 Relmada Therapeutics shares in Q4 2022, an estimated $18.3M.
  • Julian Baker first reported a position in Relmada Therapeutics in Q2 2021 and held it in 6 quarters.
  • Julian Baker's Relmada Therapeutics position peaked at $18.3M in Q3 2022.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.